全文获取类型
收费全文 | 16929篇 |
免费 | 2080篇 |
国内免费 | 249篇 |
专业分类
耳鼻咽喉 | 686篇 |
儿科学 | 425篇 |
妇产科学 | 317篇 |
基础医学 | 761篇 |
口腔科学 | 545篇 |
临床医学 | 2339篇 |
内科学 | 3447篇 |
皮肤病学 | 597篇 |
神经病学 | 1761篇 |
特种医学 | 701篇 |
外科学 | 3559篇 |
综合类 | 104篇 |
现状与发展 | 2篇 |
一般理论 | 3篇 |
预防医学 | 1438篇 |
眼科学 | 424篇 |
药学 | 603篇 |
中国医学 | 4篇 |
肿瘤学 | 1542篇 |
出版年
2024年 | 111篇 |
2023年 | 548篇 |
2022年 | 215篇 |
2021年 | 402篇 |
2020年 | 790篇 |
2019年 | 310篇 |
2018年 | 763篇 |
2017年 | 704篇 |
2016年 | 860篇 |
2015年 | 790篇 |
2014年 | 1067篇 |
2013年 | 1253篇 |
2012年 | 605篇 |
2011年 | 614篇 |
2010年 | 806篇 |
2009年 | 1024篇 |
2008年 | 617篇 |
2007年 | 489篇 |
2006年 | 594篇 |
2005年 | 455篇 |
2004年 | 393篇 |
2003年 | 361篇 |
2002年 | 329篇 |
2001年 | 258篇 |
2000年 | 187篇 |
1999年 | 266篇 |
1998年 | 303篇 |
1997年 | 325篇 |
1996年 | 357篇 |
1995年 | 334篇 |
1994年 | 209篇 |
1993年 | 160篇 |
1992年 | 216篇 |
1991年 | 213篇 |
1990年 | 133篇 |
1989年 | 182篇 |
1988年 | 171篇 |
1987年 | 141篇 |
1986年 | 170篇 |
1985年 | 159篇 |
1984年 | 155篇 |
1983年 | 108篇 |
1982年 | 114篇 |
1981年 | 88篇 |
1980年 | 88篇 |
1979年 | 76篇 |
1978年 | 70篇 |
1977年 | 73篇 |
1975年 | 68篇 |
1972年 | 64篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Our goal in this report was to determine whether symptom progression in primary lateral sclerosis (PLS) was consistent with disease spread through axonal pathways or contiguous cortical regions. The date of symptom onset in each limb and cranial region was obtained from 45 PLS patient charts. Each appearance of symptoms in a new body region was classified as axonal, contiguous, possibly contiguous, or unrelated, according to whether the somatotopic representations were adjacent in the cortex. Of 152 spread events, the first spread event was equally divided between axonal (22) and contiguous (23), but the majority of subsequent spread events were classified as contiguous. Symptom progression in PLS patients is consistent with disease spread along axonal tracts and by local cortical spread. Both were equally likely for the first spread event, but local cortical spread was predominant thereafter, suggesting that late degeneration does not advance through long axonal tracts. Muscle Nerve 49 :439–441, 2014 相似文献
32.
33.
Melissa Pilewskie MD Cristina Olcese BS Anne Eaton MS Sujata Patil PhD Elizabeth Morris MD Monica Morrow MD Kimberly J. Van Zee MS MD 《Annals of surgical oncology》2014,21(5):1552-1560
Introduction
For women with ductal carcinoma in situ (DCIS) undergoing breast-conserving surgery (BCS), the benefit of magnetic resonance imaging (MRI) remains unknown. Here we examine the relationship of MRI and locoregional recurrence (LRR) and contralateral breast cancer (CBC) for DCIS treated with BCS, with and without radiotherapy (RT).Methods
A total of 2,321 women underwent BCS for DCIS from 1997 to 2010. All underwent mammography, and 596 (26 %) also underwent perioperative MRI; 904 women (39 %) did not receive RT, and 1,391 (61 %) did. Median follow-up was 59 months, and 548 women were followed for ≥8 years. The relationship between MRI and LRR was examined using multivariable analysis.Results
There were 184 LRR events; 5- and 8-year LRR rates were 8.5 and 14.6 % (MRI), respectively, and 7.2 and 10.2 % (no-MRI), respectively (p = 0.52). LRR was significantly associated with age, menopausal status, margin status, RT, and endocrine therapy. After controlling for these variables and family history, presentation, number of excisions, and time period of surgery, there remained no trend toward association of MRI and lower LRR [hazard ratio (HR) 1.18, 95 % confidence interval (CI) 0.79–1.78, p = 0.42]. Restriction of analysis to the no-RT subgroup showed no association of MRI with lower LRR rates (HR 1.36, 95 % CI 0.78–2.39, p = 0.28). No difference in 5- or 8-year rates of CBC was seen between the MRI (3.5 and 3.5 %) and no-MRI (3.5 and 5.1 %) groups (p = 0.86).Conclusions
We observed no association between perioperative MRI and lower LRR or CBC rates in patients with DCIS, with or without RT. In the absence of evidence that MRI improves outcomes, the routine perioperative use of MRI for DCIS should be questioned. 相似文献34.
Jason Chia-Hsien Cheng MD PhD Madeline S. Graber BS Feng-Ming Hsu MD Chiao-Ling Tsai MD Leon Castaneda MS Jang-Ming Lee MD PhD Daniel T. Chang MD Albert C. Koong MD PhD 《Annals of surgical oncology》2014,21(7):2361-2368
Background and Purpose
This study was aimed at using proximity ligation assay (PLA) followed by enzyme-linked immunosorbent assay (ELISA) to identify serum biomarkers that predict treatment response and survival for patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant concurrent chemoradiotherapy (CCRT) followed by esophagectomy.Methods
Seventy-nine patients with ESCC receiving CCRT of taxane-based/5-fluorouracil-based chemotherapy and 40 Gy followed by surgery were enrolled. Serum samples were collected before and <1 month after CCRT. Fifteen biomarkers were analyzed using PLA. Biomarkers significantly correlating with pathological response/survival were verified by ELISA. Associations of the serum level of biomarkers and clinical factors with pathological response, disease-free survival (DFS), and overall survival (OS) were evaluated by analysis of variance and log-rank tests.Results
Thirty patients had complete response (38 %), 37 had microscopic residual disease (47 %), and 12 had macroscopic residual disease (15 %). With a median follow-up of 52.8 months, the median DFS was 43 months. Among the 15 biomarkers screened by PLA, vascular endothelial growth factor (VEGF)-A and transforming growth factor (TGF)-β1 were significantly associated with pathological response and/or DFS. These biomarkers were further analyzed by ELISA to confirm initial biomarker findings by PLA. After ELISA of these two markers, only VEGF-A levels were significantly correlated with pathological response. On multivariate analysis, patients with combined high pre-CCRT VEGF-A and TGF-β1 levels (greater than or equal to the median), independent of pathological response, had significantly worse DFS (11 months vs. median not reached; p = 0.007) and OS (16 vs. 46 months; p = 0.07).Conclusions
Pre-CCRT serum VEGF-A and TGF-β1 levels may be used to predict pathological response and survivals for ESCC patients receiving combined-modality therapy. 相似文献35.
Gildasio S. De Oliveira Jr. MD MSCI Ray Chang BS Seema A. Khan MD Nora M Hansen MD Jamil H. Khan BS Robert J. McCarthy PharmD Apkar V Apkarian PhD 《The breast journal》2014,20(1):9-14
Chronic pain has been shown to affect up to 60% of patients undergoing surgery for breast cancer. Besides younger age, other risk factors for the development of chronic pain have not been consistent in previous studies. The objective of the current investigation was to detect the prevalence and risk factors for the development of chronic pain after breast cancer surgery by examining a patient population from a tertiary cancer center in the United States. The study was a prospective observational cohort study. Subjects were evaluated at least 6 months after the surgical procedure. Subjects responded to the modified short form Brief pain inventory and the short form McGill pain questionnaire to identify and characterize pain. Demographic, surgery, cancer treatment, and perioperative characteristics were recorded. Propensity matching regression analysis were used to examine risk factors associated with the development of chronic pain. 300 patients were included in the study. 110 reported the presence of chronic pain. Subjects with chronic pain reported median (interquartile range [IQR]) rating of worst pain in the last 24 hours of 4 (2–5) and a median (IQR) rating on average pain in the last 24 hours of 3 (1–4) on a 0–10 numeric rating scale. Independent risk factors associated with the development of chronic pain were age, OR (95% CI) of 0.95 (0.93–0.98) and axillary lymph node dissection, 7.7 (4.3–13.9) but not radiation therapy, 1.05(0.56–1.95). After propensity matching for confounding covariates, radiation was still not associated with the development of chronic pain. Chronic pain after mastectomy continues to have a high prevalence in breast cancer patients. Younger age and axillary lymph node dissection but not radiation therapy are risk factors for the development of chronic pain. Preventive strategies to minimize the development of chronic pain are highly desirable. 相似文献
36.
37.
Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual‐energy x‐ray absorptiometry
下载免费PDF全文
![点击此处可从《Head & neck》网站下载免费的PDF全文](/ch/ext_images/free.gif)
38.
Michael P. Sarras Jr. PhD Samantha Mason RN Geoffrey McAllister BS Robert V. Intine PhD 《Wound repair and regeneration》2014,22(5):666-670
We previously reported a zebrafish model of type I diabetes mellitus (DM) that can be used to study the hyperglycemic (HG) and metabolic memory (MM) states within the same fish. Clinically, MM is defined as the persistence of diabetic complications even after glycemic control is pharmacologically achieved. In our zebrafish model, MM occurs following β‐cell regeneration, which returns fish to euglycemia. During HG, fish acquire tissue deficits reflective of the complications seen in patients with DM and these deficits persist after fish return to euglycemia (MM). The unifying mechanism for the induction of diabetic complications involves a cascade of events that is initiated by the HG stimulation of poly‐ADP ribose polymerase enzyme (Parp) activity. Additionally, recent evidence shows that the HG induction of Parp activity stimulates changes in epigenetic mechanisms that correlate with the MM state and the persistence of complications. Here we report that wound‐induced angiogenesis is impaired in DM and remains impaired when fish return to a euglycemic state. Additionally, inhibition of Parp activity prevented the HG‐induced wound angiogenesis deficiency observed. This approach can identify molecular targets that will provide potential new avenues for therapeutic discovery as angiogenesis imbalances are associated with all HG‐damaged tissues. 相似文献
39.
P. E. Kaloostian MD A. Yurter BS P. L. Zadnik BA D. M. Sciubba MD Z. L. Gokaslan MD 《Annals of surgical oncology》2014,21(1):248-262
Introduction
Management of metastatic spine disease is quite complex. Advances in research have allowed surgeons and physicians to better provide chemotherapeutic agents that have proven more efficacious. Additionally, the advancement of surgical techniques and radiosurgical implementation has altered drastically the treatment paradigm for metastatic spinal disease. Nevertheless, the physician–patient relationship, including extensive discussion with the neurosurgeon, medicine team, oncologists, radiation oncologists, and psychologists, are all critical in the evaluation process and in delivering the best possible care to our patients. The future remains bright for continued improvement in the surgical and nonsurgical management of our patients with metastatic spine disease.Methods
We include an evidence-based review of decision making strategies when attempting to determine most efficacious treatment options. Surgical treatments discussed include conventional debulking versus en bloc resection, conventional RT, and radiosurgical techniques, and minimally invasive approaches toward treating metastatic spinal disease.Conclusions
Surgical oncology is a diverse field in medicine and has undergone a significant paradigm shift over the past few decades. This shift in both medical and surgical management of patients with primarily metastatic tumors has largely been due to the more complete understanding of tumor biology as well as due to advances in surgical approaches and instrumentation. Furthermore, radiation oncology has seen significant advances with stereotactic radiosurgery and intensity-modulated radiation therapy contributing to a decline in surgical treatment of metastatic spinal disease. We analyze the entire spectrum of treating patients with metastatic spinal disease, from methods of diagnosis to the variety of treatment options available in the published literature. 相似文献40.
Tracy-Ann Moo MD Lydia Choi MD Candice Culpepper MD Cristina Olcese BS Alexandra Heerdt MD Lisa Sclafani MD Tari A. King MD Anne S. Reiner MPH Sujata Patil PhD Edi Brogi MD Monica Morrow MD Kimberly J. Van Zee MS MD 《Annals of surgical oncology》2014,21(1):86-92